Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana

Glaucoma is the leading cause of irreversible blindness worldwide. In Ghana, 19.4% of all blindness recorded is due to glaucoma. Reducing intraocular pressure medically (using eye drops) is the evidence-based therapeutic option. To determine the rational use and undertake cost analysis of anti-glauc...

Full description

Saved in:
Bibliographic Details
Published in:ClinicoEconomics and outcomes research 2021-01, Vol.13, p.619-627
Main Authors: Ofei-Palm, Charles Nii Kwade, Tagoe, Naa Naamuah, Jatoe, Dong, Agyare, Angela, Ankrah, Daniel
Format: Article
Language:English
Subjects:
Adrenergic beta blockers
Analysis
anti-glaucoma therapy
Beta blockers
Blindness
Cost analysis
Developing countries
Drug dosages
Economic aspects
Eye
ghana
Glaucoma
Health aspects
korle-bu
LDCs
Ophthalmic drugs
Original Research
Patients
Pharmacy
Prescription drugs
rational drug use
Teaching hospitals
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c576t-39d589d68a648976494a31701b6fdfb402f6bdcc07f6945e3da628c7185a5c3e3
cites cdi_FETCH-LOGICAL-c576t-39d589d68a648976494a31701b6fdfb402f6bdcc07f6945e3da628c7185a5c3e3
container_end_page 627
container_issue
container_start_page 619
container_title ClinicoEconomics and outcomes research
container_volume 13
creator Ofei-Palm, Charles Nii Kwade
Tagoe, Naa Naamuah
Jatoe, Dong
Agyare, Angela
Ankrah, Daniel
description Glaucoma is the leading cause of irreversible blindness worldwide. In Ghana, 19.4% of all blindness recorded is due to glaucoma. Reducing intraocular pressure medically (using eye drops) is the evidence-based therapeutic option. To determine the rational use and undertake cost analysis of anti-glaucoma drugs among patients attending clinic at the Lions International Eye Centre (LIEC), Korle-Bu Teaching Hospital. In this cross-sectional study, we reviewed all prescriptions presented to the pharmacy unit from 01/12/2015 to 31/03/2016. The dispensed drops were classified, and all anti-glaucoma drugs were identified. This was followed by cost analysis. A total of 588 prescriptions were captured, 27.3% (161/588) contained an anti-glaucoma medication. The mean number of anti-glaucoma medications was 1.71 of which 52.7% was prescribed to females. Prostaglandin analogs (PGA) were the most prescribed (37% (102/276)), followed by beta blockers (25.4% (70/276)), carbonic anhydrase group of medicines (16.3% (45/276)), combined beta blockers (11.2% (31/276)), alpha agonists (8.7% (24/276)) and miotics (1.4% (4/276)). The median (IQR) cost of anti-glaucoma therapy per prescription per month was GHC 65.00 (GHC38.5-GHC140) about [US$16.25 (US$ 9.6-US$35)]. Azopt (Brimonidine) was the most expensive with daily treatment cost of GHC 5.8 (about US$ 1.45), whilst the least expensive drug with a daily treatment cost of GHC 0.14 (about US$ 0.035) was timolol eye drops. Prostaglandin analogs though expensive remain the most preferred treatment for managing glaucoma at the Korle-Bu Eye Centre in Ghana. This may adversely affect treatment among the poor since prostaglandins analogs are currently not covered by insurance.
doi_str_mv 10.2147/CEOR.S311058
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5c6222253f674818903fb508d072ee3e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A672269631</galeid><doaj_id>oai_doaj_org_article_5c6222253f674818903fb508d072ee3e</doaj_id><sourcerecordid>A672269631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c576t-39d589d68a648976494a31701b6fdfb402f6bdcc07f6945e3da628c7185a5c3e3</originalsourceid><addsrcrecordid>eNptkt9r2zAQx83YWEvXtz0Pw2DsYc70w_r1MgihSwuFQteyR3GWpUTBsTLLLuS_n5ykbTImPUi6-9xXp9Nl2UeMJgSX4vvs6u5-8otijJh8k51jLGTBlcRvj_Zn2WWMK5RGqSiR6n12RktCFcXkPPs9C7HPpy002-hjDm2d30PvQzLkj9HmwSVn74t5A4MJa8gflraDzTb3bZ4Otus9dNv8OsSN71NMMs-X0MKH7J2DJtrLw3qRPf68ephdF7d385vZ9LYwTPC-oKpmUtVcAi-lErxUJVAsEK64q11VIuJ4VRuDhOOqZJbWwIk0AksGzFBLL7KbvW4dYKU3nV-ndHQAr3eG0C00pBxNYzUznKTBqOOilFgqRF3FkKyRINbutH7stTZDtba1sW3fQXMieupp_VIvwpOWhClBVBL4ehDowp_Bxl6vfTS2aaC1YYiaMIYIx0rhhH7-B12FoUtV31EpTcoZfaUWkB7gWxfSvWYU1VMuCOGK01Fr8h8qzdquvQmtdT7ZTwK-HAUsLTT9MoZmGP89noLf9qDpQoyddS_FwEiPDajHBtSHBkz4p-MCvsDP7Ub_AuSH0R0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552223653</pqid></control><display><type>article</type><title>Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana</title><source>PubMed Central(OpenAccess)</source><source>Taylor &amp; Francis Open Access(OpenAccess)</source><source>ProQuest - Publicly Available Content Database</source><creator>Ofei-Palm, Charles Nii Kwade ; Tagoe, Naa Naamuah ; Jatoe, Dong ; Agyare, Angela ; Ankrah, Daniel</creator><creatorcontrib>Ofei-Palm, Charles Nii Kwade ; Tagoe, Naa Naamuah ; Jatoe, Dong ; Agyare, Angela ; Ankrah, Daniel</creatorcontrib><description>Glaucoma is the leading cause of irreversible blindness worldwide. In Ghana, 19.4% of all blindness recorded is due to glaucoma. Reducing intraocular pressure medically (using eye drops) is the evidence-based therapeutic option. To determine the rational use and undertake cost analysis of anti-glaucoma drugs among patients attending clinic at the Lions International Eye Centre (LIEC), Korle-Bu Teaching Hospital. In this cross-sectional study, we reviewed all prescriptions presented to the pharmacy unit from 01/12/2015 to 31/03/2016. The dispensed drops were classified, and all anti-glaucoma drugs were identified. This was followed by cost analysis. A total of 588 prescriptions were captured, 27.3% (161/588) contained an anti-glaucoma medication. The mean number of anti-glaucoma medications was 1.71 of which 52.7% was prescribed to females. Prostaglandin analogs (PGA) were the most prescribed (37% (102/276)), followed by beta blockers (25.4% (70/276)), carbonic anhydrase group of medicines (16.3% (45/276)), combined beta blockers (11.2% (31/276)), alpha agonists (8.7% (24/276)) and miotics (1.4% (4/276)). The median (IQR) cost of anti-glaucoma therapy per prescription per month was GHC 65.00 (GHC38.5-GHC140) about [US$16.25 (US$ 9.6-US$35)]. Azopt (Brimonidine) was the most expensive with daily treatment cost of GHC 5.8 (about US$ 1.45), whilst the least expensive drug with a daily treatment cost of GHC 0.14 (about US$ 0.035) was timolol eye drops. Prostaglandin analogs though expensive remain the most preferred treatment for managing glaucoma at the Korle-Bu Eye Centre in Ghana. This may adversely affect treatment among the poor since prostaglandins analogs are currently not covered by insurance.</description><identifier>ISSN: 1178-6981</identifier><identifier>EISSN: 1178-6981</identifier><identifier>DOI: 10.2147/CEOR.S311058</identifier><identifier>PMID: 34239312</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Adrenergic beta blockers ; Analysis ; anti-glaucoma therapy ; Beta blockers ; Blindness ; Cost analysis ; Developing countries ; Drug dosages ; Economic aspects ; Eye ; ghana ; Glaucoma ; Health aspects ; korle-bu ; LDCs ; Ophthalmic drugs ; Original Research ; Patients ; Pharmacy ; Prescription drugs ; rational drug use ; Teaching hospitals</subject><ispartof>ClinicoEconomics and outcomes research, 2021-01, Vol.13, p.619-627</ispartof><rights>2021 Ofei-Palm et al.</rights><rights>COPYRIGHT 2021 Dove Medical Press Limited</rights><rights>2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Ofei-Palm et al. 2021 Ofei-Palm et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c576t-39d589d68a648976494a31701b6fdfb402f6bdcc07f6945e3da628c7185a5c3e3</citedby><cites>FETCH-LOGICAL-c576t-39d589d68a648976494a31701b6fdfb402f6bdcc07f6945e3da628c7185a5c3e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2552223653/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2552223653?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34239312$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ofei-Palm, Charles Nii Kwade</creatorcontrib><creatorcontrib>Tagoe, Naa Naamuah</creatorcontrib><creatorcontrib>Jatoe, Dong</creatorcontrib><creatorcontrib>Agyare, Angela</creatorcontrib><creatorcontrib>Ankrah, Daniel</creatorcontrib><title>Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana</title><title>ClinicoEconomics and outcomes research</title><addtitle>Clinicoecon Outcomes Res</addtitle><description>Glaucoma is the leading cause of irreversible blindness worldwide. In Ghana, 19.4% of all blindness recorded is due to glaucoma. Reducing intraocular pressure medically (using eye drops) is the evidence-based therapeutic option. To determine the rational use and undertake cost analysis of anti-glaucoma drugs among patients attending clinic at the Lions International Eye Centre (LIEC), Korle-Bu Teaching Hospital. In this cross-sectional study, we reviewed all prescriptions presented to the pharmacy unit from 01/12/2015 to 31/03/2016. The dispensed drops were classified, and all anti-glaucoma drugs were identified. This was followed by cost analysis. A total of 588 prescriptions were captured, 27.3% (161/588) contained an anti-glaucoma medication. The mean number of anti-glaucoma medications was 1.71 of which 52.7% was prescribed to females. Prostaglandin analogs (PGA) were the most prescribed (37% (102/276)), followed by beta blockers (25.4% (70/276)), carbonic anhydrase group of medicines (16.3% (45/276)), combined beta blockers (11.2% (31/276)), alpha agonists (8.7% (24/276)) and miotics (1.4% (4/276)). The median (IQR) cost of anti-glaucoma therapy per prescription per month was GHC 65.00 (GHC38.5-GHC140) about [US$16.25 (US$ 9.6-US$35)]. Azopt (Brimonidine) was the most expensive with daily treatment cost of GHC 5.8 (about US$ 1.45), whilst the least expensive drug with a daily treatment cost of GHC 0.14 (about US$ 0.035) was timolol eye drops. Prostaglandin analogs though expensive remain the most preferred treatment for managing glaucoma at the Korle-Bu Eye Centre in Ghana. This may adversely affect treatment among the poor since prostaglandins analogs are currently not covered by insurance.</description><subject>Adrenergic beta blockers</subject><subject>Analysis</subject><subject>anti-glaucoma therapy</subject><subject>Beta blockers</subject><subject>Blindness</subject><subject>Cost analysis</subject><subject>Developing countries</subject><subject>Drug dosages</subject><subject>Economic aspects</subject><subject>Eye</subject><subject>ghana</subject><subject>Glaucoma</subject><subject>Health aspects</subject><subject>korle-bu</subject><subject>LDCs</subject><subject>Ophthalmic drugs</subject><subject>Original Research</subject><subject>Patients</subject><subject>Pharmacy</subject><subject>Prescription drugs</subject><subject>rational drug use</subject><subject>Teaching hospitals</subject><issn>1178-6981</issn><issn>1178-6981</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkt9r2zAQx83YWEvXtz0Pw2DsYc70w_r1MgihSwuFQteyR3GWpUTBsTLLLuS_n5ykbTImPUi6-9xXp9Nl2UeMJgSX4vvs6u5-8otijJh8k51jLGTBlcRvj_Zn2WWMK5RGqSiR6n12RktCFcXkPPs9C7HPpy002-hjDm2d30PvQzLkj9HmwSVn74t5A4MJa8gflraDzTb3bZ4Otus9dNv8OsSN71NMMs-X0MKH7J2DJtrLw3qRPf68ephdF7d385vZ9LYwTPC-oKpmUtVcAi-lErxUJVAsEK64q11VIuJ4VRuDhOOqZJbWwIk0AksGzFBLL7KbvW4dYKU3nV-ndHQAr3eG0C00pBxNYzUznKTBqOOilFgqRF3FkKyRINbutH7stTZDtba1sW3fQXMieupp_VIvwpOWhClBVBL4ehDowp_Bxl6vfTS2aaC1YYiaMIYIx0rhhH7-B12FoUtV31EpTcoZfaUWkB7gWxfSvWYU1VMuCOGK01Fr8h8qzdquvQmtdT7ZTwK-HAUsLTT9MoZmGP89noLf9qDpQoyddS_FwEiPDajHBtSHBkz4p-MCvsDP7Ub_AuSH0R0</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Ofei-Palm, Charles Nii Kwade</creator><creator>Tagoe, Naa Naamuah</creator><creator>Jatoe, Dong</creator><creator>Agyare, Angela</creator><creator>Ankrah, Daniel</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8C1</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210101</creationdate><title>Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana</title><author>Ofei-Palm, Charles Nii Kwade ; Tagoe, Naa Naamuah ; Jatoe, Dong ; Agyare, Angela ; Ankrah, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c576t-39d589d68a648976494a31701b6fdfb402f6bdcc07f6945e3da628c7185a5c3e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adrenergic beta blockers</topic><topic>Analysis</topic><topic>anti-glaucoma therapy</topic><topic>Beta blockers</topic><topic>Blindness</topic><topic>Cost analysis</topic><topic>Developing countries</topic><topic>Drug dosages</topic><topic>Economic aspects</topic><topic>Eye</topic><topic>ghana</topic><topic>Glaucoma</topic><topic>Health aspects</topic><topic>korle-bu</topic><topic>LDCs</topic><topic>Ophthalmic drugs</topic><topic>Original Research</topic><topic>Patients</topic><topic>Pharmacy</topic><topic>Prescription drugs</topic><topic>rational drug use</topic><topic>Teaching hospitals</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ofei-Palm, Charles Nii Kwade</creatorcontrib><creatorcontrib>Tagoe, Naa Naamuah</creatorcontrib><creatorcontrib>Jatoe, Dong</creatorcontrib><creatorcontrib>Agyare, Angela</creatorcontrib><creatorcontrib>Ankrah, Daniel</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>ClinicoEconomics and outcomes research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ofei-Palm, Charles Nii Kwade</au><au>Tagoe, Naa Naamuah</au><au>Jatoe, Dong</au><au>Agyare, Angela</au><au>Ankrah, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana</atitle><jtitle>ClinicoEconomics and outcomes research</jtitle><addtitle>Clinicoecon Outcomes Res</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>13</volume><spage>619</spage><epage>627</epage><pages>619-627</pages><issn>1178-6981</issn><eissn>1178-6981</eissn><abstract>Glaucoma is the leading cause of irreversible blindness worldwide. In Ghana, 19.4% of all blindness recorded is due to glaucoma. Reducing intraocular pressure medically (using eye drops) is the evidence-based therapeutic option. To determine the rational use and undertake cost analysis of anti-glaucoma drugs among patients attending clinic at the Lions International Eye Centre (LIEC), Korle-Bu Teaching Hospital. In this cross-sectional study, we reviewed all prescriptions presented to the pharmacy unit from 01/12/2015 to 31/03/2016. The dispensed drops were classified, and all anti-glaucoma drugs were identified. This was followed by cost analysis. A total of 588 prescriptions were captured, 27.3% (161/588) contained an anti-glaucoma medication. The mean number of anti-glaucoma medications was 1.71 of which 52.7% was prescribed to females. Prostaglandin analogs (PGA) were the most prescribed (37% (102/276)), followed by beta blockers (25.4% (70/276)), carbonic anhydrase group of medicines (16.3% (45/276)), combined beta blockers (11.2% (31/276)), alpha agonists (8.7% (24/276)) and miotics (1.4% (4/276)). The median (IQR) cost of anti-glaucoma therapy per prescription per month was GHC 65.00 (GHC38.5-GHC140) about [US$16.25 (US$ 9.6-US$35)]. Azopt (Brimonidine) was the most expensive with daily treatment cost of GHC 5.8 (about US$ 1.45), whilst the least expensive drug with a daily treatment cost of GHC 0.14 (about US$ 0.035) was timolol eye drops. Prostaglandin analogs though expensive remain the most preferred treatment for managing glaucoma at the Korle-Bu Eye Centre in Ghana. This may adversely affect treatment among the poor since prostaglandins analogs are currently not covered by insurance.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>34239312</pmid><doi>10.2147/CEOR.S311058</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-6981
ispartof ClinicoEconomics and outcomes research, 2021-01, Vol.13, p.619-627
issn 1178-6981
1178-6981
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_5c6222253f674818903fb508d072ee3e
source PubMed Central(OpenAccess); Taylor & Francis Open Access(OpenAccess); ProQuest - Publicly Available Content Database
subjects Adrenergic beta blockers
Analysis
anti-glaucoma therapy
Beta blockers
Blindness
Cost analysis
Developing countries
Drug dosages
Economic aspects
Eye
ghana
Glaucoma
Health aspects
korle-bu
LDCs
Ophthalmic drugs
Original Research
Patients
Pharmacy
Prescription drugs
rational drug use
Teaching hospitals
title Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T09%3A42%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20Analysis%20and%20Rational%20Use%20of%20Anti-Glaucoma%20Therapy%20in%20a%20Tertiary%20Hospital%20in%20Ghana&rft.jtitle=ClinicoEconomics%20and%20outcomes%20research&rft.au=Ofei-Palm,%20Charles%20Nii%20Kwade&rft.date=2021-01-01&rft.volume=13&rft.spage=619&rft.epage=627&rft.pages=619-627&rft.issn=1178-6981&rft.eissn=1178-6981&rft_id=info:doi/10.2147/CEOR.S311058&rft_dat=%3Cgale_doaj_%3EA672269631%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c576t-39d589d68a648976494a31701b6fdfb402f6bdcc07f6945e3da628c7185a5c3e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2552223653&rft_id=info:pmid/34239312&rft_galeid=A672269631&rfr_iscdi=true